SOUTH SAN FRANCISCO, Calif., July 8, 2013 (GLOBE NEWSWIRE) -- Crescendo Bioscience, Inc., a molecular diagnostics company dedicated to developing quantitative blood tests and disease information services for rheumatoid arthritis (RA) and other autoimmune diseases, announced that Palmetto GBA, a Medicare contractor, has established national coverage for the company's Vectra DA test to aid in the assessment of disease activity in conjunction with standard clinical assessment in adults previously diagnosed with RA. With this decision, Vectra DA is now a covered benefit for Medicare beneficiaries with RA in the United States.